Francesco Pesola

416 total citations
19 papers, 237 citations indexed

About

Francesco Pesola is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Francesco Pesola has authored 19 papers receiving a total of 237 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Epidemiology. Recurrent topics in Francesco Pesola's work include Lung Cancer Research Studies (9 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Lung Cancer Treatments and Mutations (7 papers). Francesco Pesola is often cited by papers focused on Lung Cancer Research Studies (9 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Lung Cancer Treatments and Mutations (7 papers). Francesco Pesola collaborates with scholars based in Italy. Francesco Pesola's co-authors include Annamaria Catino, Pamela Pizzutilo, Domenico Galetta, Michele Montrone, Gianfranco Lauletta, Domenico Sansonno, Nicola Pansini, Vito Longo, Pietro Gatti and Franco Dammacco and has published in prestigious journals such as International Journal of Molecular Sciences, Annals of Oncology and Clinical & Experimental Immunology.

In The Last Decade

Francesco Pesola

13 papers receiving 233 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Francesco Pesola Italy 8 114 69 50 43 31 19 237
David Stones South Africa 13 173 1.5× 66 1.0× 32 0.6× 52 1.2× 43 1.4× 32 404
Laura Connell United Kingdom 7 105 0.9× 115 1.7× 17 0.3× 86 2.0× 14 0.5× 11 347
Noah Cohen United States 9 60 0.5× 35 0.5× 32 0.6× 32 0.7× 29 0.9× 20 191
Dayssy A. Diaz United States 12 151 1.3× 42 0.6× 114 2.3× 45 1.0× 14 0.5× 47 388
Elaine Wong Hong Kong 5 64 0.6× 93 1.3× 17 0.3× 70 1.6× 19 0.6× 7 320
Peter Thielsen Denmark 8 76 0.7× 113 1.6× 27 0.5× 57 1.3× 4 0.1× 17 274
Junya Arai Japan 8 39 0.3× 53 0.8× 57 1.1× 33 0.8× 5 0.2× 28 201
Ian H Gabriel United Kingdom 7 85 0.7× 102 1.5× 16 0.3× 7 0.2× 19 0.6× 14 399
Susanna Meade United Kingdom 10 39 0.3× 83 1.2× 43 0.9× 6 0.1× 17 0.5× 30 258
Tetsuo Hashida Japan 9 76 0.7× 51 0.7× 34 0.7× 7 0.2× 19 0.6× 15 341

Countries citing papers authored by Francesco Pesola

Since Specialization
Citations

This map shows the geographic impact of Francesco Pesola's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francesco Pesola with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francesco Pesola more than expected).

Fields of papers citing papers by Francesco Pesola

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francesco Pesola. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francesco Pesola. The network helps show where Francesco Pesola may publish in the future.

Co-authorship network of co-authors of Francesco Pesola

This figure shows the co-authorship network connecting the top 25 collaborators of Francesco Pesola. A scholar is included among the top collaborators of Francesco Pesola based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francesco Pesola. Francesco Pesola is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Longo, Vito, Francesco Pesola, Rosanna Lacalamita, et al.. (2024). Successful treatment of a non‐small‐cell lung cancer patient harboring HIP1‐ALK (H28:A20) and CTNNB1 p.S45del with alectinib. Thoracic Cancer. 15(31). 2283–2287. 1 indexed citations
2.
Longo, Vito, Annamaria Catino, Michele Montrone, et al.. (2024). Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go. International Journal of Molecular Sciences. 25(6). 3237–3237. 10 indexed citations
3.
Montrone, Michele, Gerardo Rosati, Vito Longo, et al.. (2023). Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. Journal of Clinical Medicine. 12(5). 1833–1833. 8 indexed citations
4.
Bavaro, Davide Fiore, Lucia Diella, Pamela Pizzutilo, et al.. (2023). Incidence and predictors of infections in patients with advanced non‐small cell lung cancer treated with checkpoint inhibitor immunotherapies: A monocentric retrospective cohort study. Scandinavian Journal of Immunology. 98(3). e13303–e13303. 3 indexed citations
5.
Catino, Annamaria, Rosanna Lacalamita, Simona De Summa, et al.. (2022). Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report. Diagnostics. 12(3). 682–682.
6.
Longo, Vito, Pamela Pizzutilo, Annamaria Catino, et al.. (2022). Prognostic factors for survival in extensive‐stage small cell lung cancer: An Italian real‐world retrospective analysis of 244 patients treated over the last decade. Thoracic Cancer. 13(24). 3486–3495. 9 indexed citations
7.
Catino, Annamaria, Domenico Galetta, Lucia Lospalluti, et al.. (2021). P78.12 A Rare Case of Dermatomyositis as Late Immune-Related Toxicity During Anti-PD1 Treatment for Advanced Lung Cancer. Journal of Thoracic Oncology. 16(3). S642–S643.
8.
Longo, Vito, Annamaria Catino, Michele Montrone, et al.. (2021). What Are the Biomarkers for Immunotherapy in SCLC?. International Journal of Molecular Sciences. 22(20). 11123–11123. 35 indexed citations
9.
Bavaro, Davide Fiore, Pamela Pizzutilo, Annamaria Catino, et al.. (2021). Incidence of Infections and Predictors of Mortality During Checkpoint Inhibitor Immunotherapy in Patients With Advanced Lung Cancer: A Retrospective Cohort Study. Open Forum Infectious Diseases. 8(6). ofab187–ofab187. 11 indexed citations
10.
Longo, Vito, Annamaria Catino, Michele Montrone, et al.. (2021). Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib. Thoracic Cancer. 12(13). 2031–2034. 1 indexed citations
11.
Bafunno, D., Annamaria Catino, Vito Longo, et al.. (2020). Smoking Prevalence, Knowledge and Perceptions on Tobacco Control Among Healthcare Professionals: A Survey in an Italian Cancer Center. Journal of Community Health. 46(3). 597–602. 6 indexed citations
12.
Longo, Vito, Annamaria Catino, Michele Montrone, et al.. (2020). Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement. JTO Clinical and Research Reports. 1(2). 100044–100044. 1 indexed citations
13.
Bafunno, D., Annamaria Catino, Gabriella Del Bene, et al.. (2020). Impact of tobacco control interventions on smoking initiation, cessation, and prevalence: a systematic review. Journal of Thoracic Disease. 12(7). 3844–3856. 42 indexed citations
14.
Prelaj, Arsela, Sara Elena Rebuzzi, Pamela Pizzutilo, et al.. (2020). EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non–Small-cell Lung Cancer Treated With Immunotherapy. Clinical Lung Cancer. 21(4). 365–377.e5. 46 indexed citations
15.
Catino, Annamaria, Livia Fucci, Domenico Galetta, et al.. (2019). EP1.04-38 A Case of Lichenoid Reaction as Late and Uncommon Immune-Related Skin Toxicity During Nivolumab Treatment. Journal of Thoracic Oncology. 14(10). S971–S972.
16.
Prelaj, Arsela, Sara Elena Rebuzzi, Pamela Pizzutilo, et al.. (2019). Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients. Annals of Oncology. 30. ii58–ii58.
17.
Prelaj, Arsela, Pamela Pizzutilo, Michele Montrone, et al.. (2018). P3.04-12 Prognostic and Predictive Role of Peripheral Blood Biomarkers in NSCLC Patients Treated with Checkpoint, a Single-Center Experience.. Journal of Thoracic Oncology. 13(10). S926–S926.
18.
Prelaj, Arsela, Sara Elena Rebuzzi, Pamela Pizzutilo, et al.. (2018). Predictive score using clinical and blood biomarkers in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy. Annals of Oncology. 29. x2–x2. 1 indexed citations
19.
Sansonno, Domenico, Gianfranco Lauletta, Pietro Gatti, et al.. (2003). Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia. Clinical & Experimental Immunology. 133(2). 275–282. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Stones Breakdown of academic impact, for papers by Laura Connell Breakdown of academic impact, for papers by Noah Cohen Breakdown of academic impact, for papers by Dayssy A. Diaz Breakdown of academic impact, for papers by Elaine Wong Breakdown of academic impact, for papers by Peter Thielsen Breakdown of academic impact, for papers by Junya Arai Breakdown of academic impact, for papers by Ian H Gabriel Breakdown of academic impact, for papers by Susanna Meade Breakdown of academic impact, for papers by Tetsuo Hashida
Rankless by CCL
2026